Magali Irla

Title: Magali Irla: Innovator in Regulatory T Cell Research

Introduction

Magali Irla is a prominent inventor based in Marseilles, France. She has made significant contributions to the field of immunology, particularly in the study of regulatory T cells. With a total of 4 patents, her work focuses on innovative approaches to treating autoimmune and inflammatory disorders.

Latest Patents

Irla's latest patents include groundbreaking research on regulatory T cells genetically modified for the lymphotoxin alpha gene. This invention relates to the use of these cells in preventing autoimmune and inflammatory disorders. The inventors demonstrated that Foxp3+CD4+ Tregs express high levels of LTα, which negatively regulates their immunosuppressive signature. They found that the adoptive transfer of LTα−/− Tregs in mice protects against dextran sodium sulfate (DSS)-induced colitis and mitigates inflammatory bowel disease (IBD), multi-organ autoimmunity, and the development of colorectal cancer (CAC). Another patent focuses on regulatory T cells targeted by a lymphotoxin alpha blocking agent, showcasing a method for treating autoimmune disorders and inflammatory-associated cancers.

Career Highlights

Throughout her career, Magali Irla has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université d'Aix-Marseille. Her research has significantly advanced the understanding of regulatory T cells and their potential therapeutic applications.

Collaborations

Irla has collaborated with Noella Lopes, contributing to the advancement of their shared research interests in immunology.

Conclusion

Magali Irla's innovative work in the field of regulatory T cells has the potential to transform treatments for autoimmune and inflammatory disorders. Her contributions continue to pave the way for future advancements in immunotherapy.